Letrozole Teva

Letrozole, the active ingredient in Letrozole Teva, is an aromatase inhibitor presented as a tablet for oral use. It reduces estrogen synthesis and is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women. By inhibiting the aromatase enzyme, Letrozole lowers circulating estrogen levels, thereby limiting the growth stimulus for estrogen‑dependent tumor cells.

GNH USA supplies Letrozole Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals, pharmacies and clinics worldwide, complying with European Union pharmacopeial standards and strict distribution protocols.

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer. - Hormone receptor‑positive breast cancer (postmenopausal): Reduces tumor growth by lowering systemic estrogen levels. - Adjuvant therapy for early‑stage breast cancer (postmenopausal): Decreases risk of disease recurrence after surgery. - Metastatic breast cancer (postmenopausal): Improves disease control and prolongs progression‑free survival.

Letrozole may cause a range of adverse reactions, which are generally categorized by frequency and severity. Common Side Effects: - Hot flashes: Sudden feeling of warmth and sweating. - Joint and muscle pain: Arthralgia and myalgia affecting mobility. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild to moderate upset stomach. - Headache: Persistent head pain. Serious or Rare Side Effects: - Severe liver injury: Elevated transaminases or hepatic failure. - Bone fracture: Increased risk due to reduced estrogen. - Thromboembolic events: Deep vein thrombosis or pulmonary embolism. - Allergic reaction: Rash, itching, or anaphylaxis.

When prescribing Letrozole, clinicians should consider several precautionary measures to minimise risks. - Monitor bone density: Assess risk of osteoporosis and consider calcium/vitamin D supplementation. - Evaluate liver function: Perform baseline and periodic liver enzyme tests. - Assess cardiovascular risk: Review history of thromboembolic disease before initiation. - Avoid use in premenopausal women: Hormonal status must be confirmed as postmenopausal. - Use caution in patients with severe osteoporosis: Consider alternative therapy if fracture risk is high. - Store at room temperature: Keep in original packaging, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, altering its efficacy or increasing toxicity. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Decrease Letrozole plasma levels, reducing effectiveness. - Anticoagulants (warfarin): May enhance anticoagulant effect, increasing bleeding risk. - Tamoxifen: Combined use can antagonize therapeutic benefit. Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): May increase risk of bone loss. - Cholesterol‑lowering agents (statins): Potential for altered metabolism, monitor liver function.